ClinicalTrials.gg
CompletedNCT04619056Updated May 12, 2026

First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma

A Phase 1 interventional study of CEB-01 membrane loaded with SN-38 in Locally Advanced Soft Tissue Sarcoma and Recurrent Soft Tissue Sarcoma, sponsored by CEBIOTEX. Completed at 5 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by CEBIOTEX · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2020, registered Oct 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing irinotecan in Sarcoma — 2 open to participants now, 3 under way, none of them phase 3. Irinotecan · Sarcoma.

Enrollment
13th of 16
21 · median 35
Started
2020
the only one that year
Phase 1
2 of 16
none open now
Registered
15th of 16
by date

Among the 16 studies testing irinotecan in Sarcoma, this one is the 13th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1, and was the 15th registered.

Sarcoma

1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

2 of the 16 studies testing irinotecan in Sarcoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About irinotecan

Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing irinotecan in Sarcoma, or all of them as a file.
02

Study summary

This is an open label, first-in-man clinical trial to assess safety and tolerability of CEB-01 PLGA membrane in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma after surgery.

The trial will be conducted in 3 dose-escalation cohorts (3 patients each, enrolling patients one by one, after 4 weeks of observation and agreement of Scientific Committee and DMC) and in an expansion cohort, using the highest safe and tolerable dose. The study will follow a 3+3 modified design; dose escalation will follow a modified Fibonacci method. CEB-01 carrying a SN-38 dose between 9 and 36 mg will be placed in the surgical bed at the time of tumor resection.

Read the detailed description

CEB-01 is a poly(lactic-co-glycolic acid) (PLGA) polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.

CEB-01 carrying a SN-38 dose between 9 and 36 mg will be administered. CEB-01 will be placed on all surfaces that were in contact with and/or were infiltrated by the tumor.

Confirmatory central reviewing of diagnosis will be performed for all patients, using tumor samples obtained during surgery; additionally, patients will also be included according to local Pathological Anatomy (PA) diagnosis.

Patients will be followed-up once every week during the first 8 weeks of the study, and then every 2 weeks up to 12 weeks after implantation of CEB-01. Thereafter, follow-up schedule will be as per normal practice until study completion.

Efficacy assessment will be performed by Magnetic Resonance Imaging (MRI) [Computed tomography (CT) scan and Positron Emission Tomography (PET-CT) are also allowed] according to RECIST 1.1 criteria. Baseline image determination will be performed at week 12 (±3 days) after surgery; if the image analysis is not conclusive due to wound healing in the tumor bed, it will be repeated on week 16 (±3 days) post-surgery, and every 12 weeks thereafter.

A pharmacokinetic assessment of SN-38 will be performed in all patients, and the Cmax, Tmax, half-life, and area under the time-drug concentration curve (AUC) of the drug will be determined. Blood samples will be collected at baseline and at 8 time points after CEB-01 implantation.

Assessment of adverse events, safety, and toxicity will be performed according to the Common Terminology Criteria for Adverse Events (CTCAE - version 5.0) at each patient visit from the time of Informed Consent until the end of the study.

Quality of Life based on EORTC Quality of Life Questionnaire (QLQ) 30 will be measured prior surgery, at month 1 and month 3.

03

Conditions studied

  • Locally Advanced Soft Tissue Sarcoma
  • Recurrent Soft Tissue Sarcoma

Keywords

  • Soft tissue sarcoma
  • Retroperitoneal
  • Recurrent or locally advanced
  • CEB-01 PLGA membrane
  • SN-38
  • Local drug delivery system
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18 years.
  2. confirmed diagnosis of locally advanced (T3 -T4, American Joint Committee on Cancer (AJCC)/primary tumor, regional lymph nodes, and distant staging system (TMN) 8th Edition) and/or (any) retroperitoneal soft tissue sarcoma (liposarcoma, leiomyosarcoma, a solitary fibrous tumor (SFT), pleomorphic sarcoma, or a malignant nerve sheath tumor). Patients with local advanced (T3 -T4,AJCC/TMN 8th Edition) and/or relapse and metastatic disease who are candidates for local surgery without option of systemic treatment, are also eligible for the trial.
  3. Pathology specimens available for centralized review. Submission of formalin-fixed paraffin-embedded (FFPE) tumor tissue for central reviewing is required; if a FFPE block cannot be provided, then 10 unstained, positively-charged slides of 4-5 um thickness must be submitted.
  4. Size of tumor (visible or previously inadequately resected) >5 cm at instrumental staging (CT, MRI).
  5. Normal liver, renal, hematological, and cardiac function as defined by biochemical and hematological parameters as follows: >11 g/dL, >100.000/mm3, White Blood Cells (WBC) >3000/mm3, >1500/mm3, albumin >3.0 g/dl, (ALT) and Aspartate Aminotransferase (AST) \<2.5 times the upper limit of normality (), \<2 times the ULN, creatinine \<1.5 mg/dl or > 60 ml/min.
  6. (ECOG) Performance Status \<2.
  7. No concomitant radiotherapy or chemotherapy planned.
  8. greater than 6 months.
  9. Female subjects of must have a negative urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening.
  10. Men and women of childbearing potential must be willing to use adequate throughout the study and for 3 months after surgery.
  11. Ability to understand and the willingness to sign a written document; subject has signed an Informed Consent Form (ICF) prior to any screening procedures and is able to comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or lactation. Note: Pregnant women are excluded from this study; if the patient is a lactating mother, breastfeeding should be discontinued.
  2. Other within past 5 years, with the exception of carcinoma in situ of cervix and basocellular skin cancers treated with eradicating intent.
  3. Serious psychiatric disease that precludes or limits compliance
  4. Medical condition limiting survival to less than 6 months.
  5. Uncontrolled bacterial, viral or fungal infection.
  6. Active viral hepatitis or chronic liver disease.
  7. Impossibility of ensuring adequate follow-up.
  8. to magnetic resonance imaging (MRI), including presence of a pacemaker or an aneurysm clip, severe claustrophobia, a known reaction to the gadolinium contrast dye, or body weight that could interfere with the feasibility of a MRI.
  9. Major surgery within 14 days prior to starting study drug or still in recovery after experiencing surgical complications; neither tumor nor central line insertion are considered a major surgery.
  10. Unable or unwilling to stop the use of herbal supplements; the use of nutritional supplements may be allowed after review by a study pharmacist to confirm no significant risk of interaction with eribulin or radiation.
  11. Other relevant concomitant illnesses.
  12. Patients previously treated with Irinotecan.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Cohort 1

    CEB-01 with total SN-38 dose: 9 mg

    Drug: CEB-01 membrane loaded with SN-38

  • Experimental
    Cohort 2

    CEB-01 with total SN-38 dose: 18 mg

    Drug: CEB-01 membrane loaded with SN-38

  • Experimental
    Cohort 3

    CEB-01 with total SN-38 dose: 36 mg

    Drug: CEB-01 membrane loaded with SN-38

Interventions

  • DrugCEB-01 membrane loaded with SN-38

    Drug pages: CEB-01 · Irinotecan

    CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.

06

What researchers measure

Primary outcomes

  1. Recommended Doses for Phase II (Maximum tolerated dose)

    The number of patients experiencing dose limiting toxicities during the Dose Limiting Toxicities (DLT) observation period of 2 weeks.

    Time frame: Through 2 weeks

Secondary outcomes

  1. Frequency of Adverse Events (AEs) (Safety)

    Frequency of adverse events reported classified by type and severity.

    Time frame: Through study completion, average 2 years

  2. Frequency of Treatment Related Adverse Events (TRAEs) (Toxicity)

    Frequency of treatment related adverse events reported classified by type and severity.

    Time frame: Through study completion, average 2 years

  3. Time to local relapse (TTLR)

    Time from the start of treatment to the date of local relapse according to the RECIST 1.1 criteria, or death due to any cause. Those patients who are alive and have not relapsed at the last follow-up, will be censored at the date of the last follow-up. Relapse definition: For patients in which R0 is obtained by surgery, relapsed should be considered when disease reappears with size \> 1 cm (measurable disease). For patients with R1 or R2, RECIST 1.1 guideline should be used for disease progression definition.

    Time frame: Through study completion, average 2 years

  4. Progression Free Survival (PFS)

    Time from the start of treatment to the date of the first progression according to the RECIST 1.1 criteria, or death due to any cause. Those patients who are alive and have not progressed at the last follow-up, date of progression will be censored at the date of the last follow-up.

    Time frame: Through study completion, average 2 years

  5. Overall Survival (OS)(until 24 months of Follow Up (FU))

    Median of overall survival. Time from the start of the trial treatment to the date of exitus for any cause. In those patients who are alive at the last follow-up, OS will be censored by the date of the last follow-up in which the patient was alive.

    Time frame: Through study completion, average 2 years

  6. Quality of life: EORTC QLQ 30

    Questionnaire developed and validated to assess the quality of life of cancer patients.

    Time frame: Prior to surgery, at month 1 and month 3 after surgery

07

Study locations

5 sites
  • Hospital Universitario Vall d'Hebron
    Barcelona, Barcelona 08035, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Catalonia 08041, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, Madrid 28007, Spain
  • Fundación Jiménez Díaz
    Madrid, Madrid 28040, Spain
  • Hospital Universitario y Politécnico La Fe
    Valencia, Valencia 46026, Spain
08

References and documents

Publications

  • Sebio A, Gonzalez JA. ASO Author Reflections: Preventing Local Recurrence After Surgery in Retroperitoneal Sarcoma with CEB-01, a SN-38-Releasing Membrane. Ann Surg Oncol. 2026 Aug;33(8):7714-7715. doi: 10.1245/s10434-026-19638-6. Epub 2026 Apr 15. No abstract available. PubMed 41984421 ↗
  • Gonzalez JA, Sebio A, Martin-Broto J, Hindi N, Villarejo-Campos P, Jimenez M, Diaz-Beveridge R, Orbis Castellanos JF, Lopez Andujar R, Alvarez Alvarez R, Asencio JM, Serrano C, Rodriguez Conde N, Castro Boix S, Krauel L, Colom Codina H, Tornero Garcia JA, Lopera de Llanos E, Huguet Ninou A, Perez Campos A, Gruber AK, Lopez Pousa A. ASO Visual Abstract: First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas. Ann Surg Oncol. 2026 Aug;33(8):7717-7718. doi: 10.1245/s10434-026-19614-0. No abstract available. PubMed 41984420 ↗
  • Gonzalez JA, Sebio A, Martin-Broto J, Hindi N, Villarejo-Campos P, Jimenez M, Diaz-Beveridge R, Orbis Castellanos JF, Lopez Andujar R, Alvarez Alvarez R, Asencio JM, Serrano C, Rodriguez Conde N, Castro Boix S, Krauel L, Colom Codina H, Tornero Garcia JA, Lopera de Llanos E, Huguet Ninou A, Perez Campos A, Gruber AK, Lopez Pousa A. First-in-Human Study of CEB-01: Novel Loco-Regional SN-38-Releasing Membrane to Prevent Local Recurrence in Retroperitoneal Sarcomas. Ann Surg Oncol. 2026 Aug;33(8):7677-7687. doi: 10.1245/s10434-026-19487-3. Epub 2026 Apr 17. PubMed 41998462 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Nov 2025, 65 months.

Of 72 industry-sponsored phase 1 interventional studies under Sarcoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 66. This study's 65 months is above that.

Counting every sponsor, half of 161 studies reached it within 56 months; a quarter within 35 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2020
First posted
Nov 6, 2020
StartActual
Jun 3, 2020
Primary completionActual
Nov 28, 2025
CompletionActual
Nov 28, 2025
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04619056
Lead sponsor
CEBIOTEX
Responsible party
Sponsor
First posted
Nov 6, 2020
Start date
Jun 3, 2020
Primary completion
Nov 28, 2025
Completion
Nov 28, 2025
Last update
May 12, 2026

Study contacts

Ana Sebio, M.D. Ph.D.
study chair · Hospital Universitari de la Santa Creu i Sant Pau

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CEB-01 · Irinotecan

Start the discussion